29 May 2020
Year Ended 31 December 2019
Concepta PLC (AIM: CPT), the innovative UK personalised healthcare company and developer of myLotus®, the UK's most accurate home-use fertility tracking and pregnancy self-testing system, announces final results for the year ended 31 December 2019.
- myLotus first pregnancies and births announced
- Supply to Boots.com
- Leases and assets for Doncaster manufacturing site assigned to third party in April 2020
- Contract manufacturing agreement signed April 2020
- Appointment of Madeleine Kennedy as Chief Financial Officer & Secretary in October 2019
- Appointment of Penelope McCormick as Chief Executive Officer in November 2019
- Appointment of Lyn Rees as Non-executive Director in November 2019
- EBITDA loss £2.2m
- Cash at year end £0.62m
- £2.2m (net of issue expenses) share placing secured in April 2019
- £1.7m (net of issue expenses) share placing secured in April 2020
Commenting on Outlook, Penny McCormick, Chief Executive Officer of Concepta plc, said:
"As we roll out our commercial strategy and continually improve our cost base, we are confident of building sustainable growth, and an ability to invest in a portfolio that meets the needs of our customers. Underpinned by our increasing focus on the digital marketing and education effort from mid-2020, we expect to see good commercial traction of myLotus and take advantage of up-coming connected personal diagnostic technology innovation and industry know-how to drive our growth strategy."
The full Group Annual Report and Financial Statements are available here: www.conceptaplc.com
Penny McCormick , Chief Executive Officer
via Walbrook PR
Maddy Kennedy, Chief Financial Officer
SPARK Advisory Partners Limited (NOMAD)
Tel: +44 (0)20 3368 3550
Novum Securities (Broker)
Tel: +44 (0)20 7399 9400
Walbrook PR Ltd (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or [email protected]
Mob: +44(0)7980 541 893
About Concepta PLC ( www.conceptaplc.com )
Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.
myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2020.
myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.